Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.
The cognitive effects of multiple sclerosis are often associated with later stages of the disease. However, there may be some indicators of its involvement in patients with early stages. Understanding these factors — some of which are psychological and some of which are clinical — could help with treating and monitoring patients.
A team of researchers assessed the Secondary Progressive Risk Score (SP-RiSc) on its ability to identify patients at elevated risk of secondary progressive MS.
Neurology Advisor spoke with Klaus Schmierer, MBBS, PhD, to discuss new evidence suggesting a protective antibody response following vaccination in patients with MS taking MAVENCLAD.
The study found worsening disease in those with thinning in the ganglion cell layer plus inner plexiform layer plus peripapillary retinal nerve fibre layer.
To determine the effectiveness of the Risk of Ambulatory Disability (RoAD) score, study researchers evaluated the prognosis of patients with relapsing-remitting MS.
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
There may be numerous risk factors and outcomes associated with SARS-CoV-2 infection in patients with multiple sclerosis.
Investigators sought to better understand the pathological correlates associated with increased serum GFAP in the normal appearing white matter of patients with multiple sclerosis.
A team of researchers assessed the Novartis-Oxford Multiple Sclerosis data set to investigate the relationship between age, relapse frequency, and phenotypic presentation of multiple sclerosis.
